Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic dermatitis and delves into each option ...

Jason B. Pieper, DVM, MS, DACVD: …It is tough when we talk about atopic dermatitis, I mean, there's a variety [of causes].

If someone has atopic dermatitis during childhood, it’s likely they’ll have recurrent flares and need recurrent treatment. However, parents can help minimize their child’s flares by ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...